Clinical Trials Logo

Ocular Melanoma clinical trials

View clinical trials related to Ocular Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05187884 Active, not recruiting - Ocular Melanoma Clinical Trials

Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

NADOM
Start date: May 3, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the feasibility and tolerability of neo-adjuvant/adjuvant Darovasertib on uveal melanoma patients. Who is it for? Patients may be eligible to join this study with high-risk uveal melanoma and planned to undergo enucleation Study details: Eligible patients will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a day as a starting dose) and once determiend safe then up to 6 months after fulfilling inclusion/exclusion criteria and consent. Select patients will undergo adjuvant treatment for 6 months based on their initial response. It is hoped that this research will provide insight into the safety and tolerability of Darovasertib. Furthermore, it aims to document the pharmacodynamic and pharmacokinectic effects of Darovasertib on uveal melanoma patients.

NCT ID: NCT04417530 Active, not recruiting - Uveal Melanoma Clinical Trials

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Start date: August 5, 2020
Phase: Phase 2
Study type: Interventional

The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).

NCT ID: NCT04364230 Active, not recruiting - Melanoma Clinical Trials

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Mel66
Start date: September 28, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.

NCT ID: NCT03528408 Active, not recruiting - Melanoma Clinical Trials

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Start date: July 26, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-site, single-arm Phase 2 study of adjuvant nivolumab combined with ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metastatic disease. All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, patient request to discontinue or completion of treatment. Subjects may receive up to 25 doses of nivolumab and 8 doses of ipilimumab